SG Americas Securities LLC Acquires 7,284 Shares of Cencora, Inc. (NYSE:COR)

SG Americas Securities LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 21.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,762 shares of the company's stock after purchasing an additional 7,284 shares during the period. SG Americas Securities LLC's holdings in Cencora were worth $9,400,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in COR. Kingswood Wealth Advisors LLC purchased a new stake in shares of Cencora during the second quarter valued at approximately $655,000. TD Asset Management Inc bought a new stake in shares of Cencora in the 1st quarter worth $95,313,000. LSV Asset Management purchased a new position in shares of Cencora in the first quarter worth $3,579,000. Cairn Investment Group Inc. bought a new position in shares of Cencora during the first quarter valued at $2,294,000. Finally, Lake Street Advisors Group LLC purchased a new stake in shares of Cencora during the first quarter valued at $836,000. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company's stock, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company's stock, valued at $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. Corporate insiders own 15.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on COR. Bank of America restated a "neutral" rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Robert W. Baird dropped their target price on Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research report on Friday, September 6th. Finally, StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $256.67.

Cencora Stock Performance

Shares of NYSE:COR traded down $1.02 during mid-day trading on Friday, reaching $219.94. 1,638,164 shares of the company traded hands, compared to its average volume of 1,415,768. Cencora, Inc. has a 52 week low of $182.62 and a 52 week high of $247.66. The firm has a market cap of $43.87 billion, a PE ratio of 24.06, a PEG ratio of 1.58 and a beta of 0.44. The company's 50 day moving average price is $234.60 and its 200-day moving average price is $232.07. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same period last year, the firm earned $2.92 EPS. The company's revenue was up 10.8% on a year-over-year basis. On average, equities analysts expect that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's dividend payout ratio (DPR) is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.